Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,378 across all filing types
Latest filing 2019-12-10 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES ENROLLMENT TARGET REACHED IN THE GLOBAL PHASE III VOYAGER TRIAL OF AVAPRITINIB IN CHINESE PATIENTS WITH THIRD-LINE GIST
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the completion of enrollment in a Phase III clinical trial (VOYAGER trial) for a drug candidate, avapritinib. It provides detailed information about the trial, drug development status, regulatory submissions planned, and company strategy. There are no financial statements, quarterly or annual results, or audit information. The document is not a report but an announcement of clinical trial progress and corporate updates related to drug development. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a regulatory filing in the sense of compliance or officer certification. It is not related to shareholder votes, capital changes, or management changes. The content is primarily a corporate announcement about clinical trial enrollment and drug development progress, which is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2019-12-10 English
GRANT OF SHARE OPTIONS
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the grant of share options to employees under the company's Post-IPO Employee Share Option Plan (ESOP). It details the number of options granted, subscription price, vesting schedule, and the purpose of the grants. The document references compliance with the Listing Rules and is clearly an announcement of a capital-related event (share options granted). It is not a full financial report, audit, or management discussion, nor is it a voting result or AGM material. It is specifically about a share option grant, which falls under capital or financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive announcement, not a brief notice or report publication announcement.
2019-12-09 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES PROMISING ANTITUMOR ACTIVITY AND SAFETY ON ITS ANTI-PD-L1 ANTIBODY IN RR-ENKTL PATIENTS WITH A COMPLETE RESPONSE RATE OF 33.3%
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals reporting updated clinical trial results for their anti-PD-L1 antibody in a specific cancer patient population. It includes detailed clinical trial data, efficacy and safety results, and commentary from company executives. The document is not a full financial report, audit, or regulatory filing, nor is it a transcript, presentation, or voting result. It is a corporate announcement focused on clinical trial progress and drug development updates. Given the nature of the content and the fact it is an announcement rather than a full report, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories. The document length (9544 characters) and detailed content support this classification with high confidence.
2019-12-09 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF MEMBER OF SENIOR MANAGEMENT
Board/Management Information Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the appointment of a new member of senior management, Ms. Shirley Zhao, as General Manager for Greater China and Head of Commercial. It provides biographical details and the effective date of the appointment. There is no financial data, no mention of a report or financial results, and the content focuses solely on management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3461 characters, which is relatively short but contains substantive information about management appointment, not just a brief notice or report publication announcement. Therefore, the appropriate classification is MANG with high confidence.
2019-12-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/11/2019. The content focuses on share capital changes, issuance, and confirmations related to securities listing compliance. There is no indication of financial performance data, earnings, management discussion, or legal proceedings. The document is a regulatory filing reporting share capital movements and compliance confirmations to the stock exchange, typical of a regulatory announcement rather than a full financial report or earnings release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-12-05 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2019-12-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.